NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
STENOCARE A/S ("STENOCARE") hereby announce that the company has signed a new agreement to source medical cannabis products from the Canadian company AgMedica Bioscience Inc ("AgMedica"). STENOCARE and AgMedica is already working with relevant health authorities to have their products made available for distribution.
STENOCARE is a supplier of prescription-based medical cannabis products for patients' treatment. The company has experience delivering prescription-based medical cannabis products for patients in Denmark and Sweden. Together with AgMedica the company will now commence the process with relevant health authorities to make their products available for patients in several markets.
AgMedica Bioscience Inc., a licensed producer of cannabis based in Chatham, Ontario, Canada, is committed to becoming a global leader in the development and commercialization of cannabis and cannabis-derived products. The company is evolving with the cannabis industry by focusing its efforts on the development and commercialization based on a pharmaceutical mindset, international quality certifications and high-quality products. Every product goes through an over 600-step quality assurance process in their indoor cultivation and production facility.
STENOCARE and AgMedica have worked closely together to pre-qualify their products and cultivation and production methods. STENOCARE and AgMedica has started the work to make products commercially available with STENOCARE's distribution setup.
Thomas Skovlund Schnegelsberg, CEO of STENOCARE is commenting:
"Today we realize yet another important milestone in our STENOCARE 2.0 growth plan with the announcement of our partnership with AgMedica. AgMedica has a proven track record within medical cannabis in Canada and internationally, and the new supply agreement will source premium products for new markets that we plan to start serving together in 2022."
Dr. Trevor Henry, CEO of AgMedica:
"We are delighted to partner with STENOCARE and this is a further important step in our strategy of developing robust and sustainable international sales channels. We are convinced that our unwavering commitment to high-quality products will result in the future expansion of the international cannabis market for both AgMedica and STENOCARE."
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: firstname.lastname@example.org
STENOCARE's Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: email@example.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.
www.stenocare.com www.stenocare.dk www.stenocare.se
(c) 2021 Cision. All rights reserved., source Press Releases - English